Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shuganjieyu Capsules and digital Taiji for emotional and sleep disorders after traumatic brain injury
ChiCTR2300074492Phase 4Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Feb 2023
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Shugan Jieyu in major depressive disorder (MDD), anxiety disorder, sleep disorder and 1 more (3 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Change in HAMD-17 total score from baseline at 12 weeks. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
Shugan Jieyu
03
Conditions
major depressive disorder (MDD)anxiety disordersleep disordertraumatic brain injury (TBI)
Beyond the preview
Go deeper on ChiCTR2300074492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074492.